Compare Enveric Biosciences Inc (ENVB) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs T-Mobile Us Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while T-Mobile Us Inc trades at $158.55 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 27023.5× Enveric Biosciences Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and T-Mobile Us Inc for 84 Days on average.
| ENVB | TMUS | |
|---|---|---|
Market Cap | $6.80M | $183.76B |
Volume | 64,867 | 4,294,650 |
Sector | Health | Media |
52-Week High | $10.80 | $230.06 |
52-Week Low | $1.27 | $161.73 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | -$1.49M | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
T-Mobile US (TMUS) trades at $167.62, up 1.02% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $88.31B revenue in 2025, 11.45% net margin, and consistent earnings beats in recent quarters. Recent developments include a 15% dividend increase to $1.17 per share and participation in a joint venture with AT&T and Verizon to expand satellite connectivity.
TMUS presents a compelling investment case with strong analyst support (79.6% buy ratings) and a $231.10 price target representing 38% upside. However, risks include $84.6B debt load, increasing debt-to-asset ratio (39.35% in 2025), and competitive pressures in the wireless industry. The stock offers growth potential through 5G expansion and AI-driven network improvements while maintaining dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
